Archived story2 articles · 2 publishers
AstraZeneca invests $2bn in US firm for cancer drug tie-up
- Published
- Updated
- Reports
- 2 from 2 publishers
AstraZeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a cancer research collaboration. The FTSE 100 company will buy 109,000 shares at $18.36 each, with the firms working on Summit's experimental medicine and potential combinations with AstraZeneca treatments.
AI summary · Original reporting is linked alongside
Morning briefing · the United Kingdom · free
The 10 stories everyone is covering in the United Kingdom, in your inbox at 7 am your time.
grouped.news is free, independent and has no paywall. If it saves you time, chip in.Buy us a coffee ↗